{"id":613282,"date":"2022-08-25T07:00:02","date_gmt":"2022-08-25T07:00:02","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=613282"},"modified":"2022-08-25T07:00:02","modified_gmt":"2022-08-25T07:00:02","slug":"immune-thrombocytopenia-itp-pipeline-assessment-fda-ema-and-pmda-approvals-emerging-drugs-clinical-trials-therapeutic-analysis-growth-prospects-and-key-companies-by-delveinsight","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/immune-thrombocytopenia-itp-pipeline-assessment-fda-ema-and-pmda-approvals-emerging-drugs-clinical-trials-therapeutic-analysis-growth-prospects-and-key-companies-by-delveinsight_613282.html","title":{"rendered":"Immune thrombocytopenia (ITP) Pipeline Assessment – FDA, EMA, and PMDA Approvals, Emerging Drugs, Clinical Trials, Therapeutic Analysis, Growth Prospects, and Key Companies by DelveInsight"},"content":{"rendered":"
\n
\"Immune<\/a><\/div>\n
\n
Immune thrombocytopenia Pipeline<\/div>\n<\/div>\n<\/div>\n

Immune thrombocytopenia pipeline constitutes 30+ key companies continuously working towards developing 30+ Immune thrombocytopenia treatment therapies, analyzes DelveInsight<\/em><\/strong><\/p>\n

 <\/p>\n

Immune thrombocytopenia (ITP) is a disorder that can lead to easy or excessive bruising and bleeding. The bleeding results from unusually low levels of platelets — the cells that help blood clot.Formerly known as idiopathic thrombocytopenic purpura, ITP can cause purple bruises, as well as tiny reddish-purple dots that look like a rash.<\/p>\n

 <\/p>\n

“Immune thrombocytopenia Pipeline Insight, 2022<\/strong><\/a>” report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Immune thrombocytopenia Market. <\/p>\n

The Immune thrombocytopenia Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers, acquisition, funding, designations, and other product-related details.<\/p>\n

 <\/strong><\/p>\n

\"\"<\/strong><\/p>\n

 <\/p>\n

DelveInsight’s Report covers around 30+ products under different phases of clinical development like<\/strong><\/p>\n

• Late-stage products (Phase III)<\/p>\n

• Mid-stage products (Phase II)<\/p>\n

• Early-stage product (Phase I)<\/p>\n

• Pre-clinical and Discovery stage candidates<\/p>\n

• Discontinued & Inactive candidates<\/p>\n

• Route of Administration<\/p>\n

 <\/p>\n

Immune thrombocytopenia– Emerging Drugs Under Different Phases of Clinical Development Include:<\/strong><\/p>\n

• Rozandixizumab (UCB7665): UCB<\/p>\n

• Efgartigimod: arGEN-X<\/p>\n

 <\/p>\n

Further product details are provided in the Immune thrombocytopenia report. Download the report to learn more about the Immune thrombocytopenia emerging therapies at:   <\/strong><\/p>\n

https:\/\/www.delveinsight.com\/sample-request\/immune-thrombocytopenia-itp-pipeline-insight<\/strong><\/a><\/p>\n

 <\/p>\n

 Immune thrombocytopenia Pipeline Analysis<\/strong><\/p>\n

The report provides insights into: <\/strong><\/p>\n